Key result
Plasma B-type natriuretic peptide levels > 2460.5 pg/ml independently predicted the development of acute heart failure secondary to supraventricular tachycardia in neonates (OR 2.281).
Why the study?
SVT is a common non-benign neonatal arrhythmia that can cause cardiac decompensation, prompting investigation into early risk factors for secondary AHF and their role in guiding anti-arrhythmic treatment.
Does plasma BNP level predict acute heart failure and the need for second-line anti-arrhythmic treatment in neonates with supraventricular tachycardia?
Observational (n=43)
No
Does plasma BNP level predict acute heart failure and the need for second-line anti-arrhythmic treatment in neonates with supraventricular tachycardia?
In neonates with SVT, a BNP level > 2460.5 pg/ml predicts the development of acute heart failure and the need for second-line anti-arrhythmic therapy.
Answers are grounded in this paper and cite their sources.
May support BNP measurement to anticipate AHF in neonatal SVT; leaves open prospective validation before guiding therapy.
Background Supraventricular tachycardia (SVT) is one of the most common non-benign arrhythmias in neonates that could lead to cardiac decompensation. This study investigated early risk factors of acute heart failure (AHF) secondary to SVT in neonates, and explored their value on guiding the selection of efficient anti-arrhythmic treatment. Methods A total of 43 newborns with SVT diagnosed and treated between January 2017 and December 2022 were analyzed. According to the presence of AHF after initial restoring SVT to sinus rhythm, newborns were divided into SVT with AHF group and SVT without AHF group, and the clinical data and anti-arrhythmic therapies were analyzed. Risk factors of AHF secondary to SVT in neonates were determined by logistic regression. The cut-off value for predictors of AHF secondary to SVT and demanding of a second line anti-arrhythmic treatment was determined by receiver operating characteristic curve analysis. Results Time to initial control of tachycardia > 24h, hyperkalemia, anemia, plasma B-type natriuretic peptide (BNP) were risk factors of AHF secondary to SVT in neonates. BNP exhibited AUC of 0.804 in predicting AHF, and BNP > 2460.5pg/ml (OR 2.281, 95% CI 1.270 ~ 45.399, P = 0.026) was an independent predictor yielded sensitivity of 70.59% and specificity of 84.62%. The neonates with BNP > 2460.5pg/ml (37.5% versus 7.4%, P = 0.037) had a higher demand for a second line anti-arrhythmic treatment to terminate SVT, and the sensitivity and and specificity for BNP in predicting were 75.0%, 71.4%, respectively. Conclusions BNP could be used to predict an incident of AHF secondary to SVT and a demand of second line anti-arrhythmic treatment for terminating SVT hastily to prevent decompensation in neonates.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2023) conducted an observational in Supraventricular tachycardia (SVT) (n=43). Plasma B-type natriuretic peptide (BNP) > 2460.5 pg/ml vs. BNP ≤ 2460.5 pg/ml was evaluated on Acute heart failure (AHF) secondary to SVT (OR 2.281, 95% CI 1.270-45.399, p=0.026). Plasma B-type natriuretic peptide levels > 2460.5 pg/ml independently predicted the development of acute heart failure secondary to supraventricular tachycardia in neonates (OR 2.281).
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: